Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 8/2021

01-08-2021 | Human Immunodeficiency Virus | Original Paper

Predictors of Event-Driven Regimen Choice in Current PrEP Users and Sexual Behavior Characteristics of MSM Receiving Sexual Health Services in New York City

Authors: Pedro B. Carneiro, Christopher Rincon, Sarit Golub

Published in: AIDS and Behavior | Issue 8/2021

Login to get access

Abstract

While daily PrEP is undeniably effective, broad-based adoption remains low. Non-daily PrEP modalities, like event-driven PrEP (ED PrEP), offer an efficient way to deliver PrEP’s protection to priority populations. We carried out an at-home survey with patients receiving sexual health services in a LGBTQ-clinic in New York (n = 147). Participants answered questions on ED PrEP awareness and preferences, sexual behavior, and sexual preparatory practices. Only 50% of our sample were aware of ED PrEP, about 30% met eligibility for ED PrEP, and 35% chose ED PrEP as a good HIV prevention option for them. In a robust Poisson model (n = 128), endorsement of ED PrEP as a good prevention choice was significantly more common in participants who were uninsured, preferred taking PrEP only when needed, and those who had concerns about side-effects. Furthermore, participants reported many sexual behaviors patterns and preparatory practices compatible with use of ED PrEP.
Literature
1.
CDC. Estimated HIV incidence and prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report. Atlanta: CDC; 2020.
2.
Grant RM, Anderson PL, Mcmahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRef
3.
Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75.CrossRef
4.
Mccormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRef
5.
CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 update: a clinical practice guideline. Atlanta: CDC website; 2018.
6.
Smith D, Van Handel M, Grey J. By race/ethnicity, blacks have highest number needing PrEP in the United States, 2015. Paper presented at the Conference on retroviruses and Opportunistic Infections 2018.
7.
AVAC. United States—PrEPWatch [Internet]. 2018.
8.
Elion RA, Kabiri M, Mayer KH, Wohl DA, Cohen J, Beaubrun AC, et al. Estimated impact of targeted pre-exposure prophylaxis: strategies for men who have sex with men in the United States. Int J Environ Res Public Health. 2019;16(9):1592.CrossRef
9.
Patel R, Singh S, Farag C, et al. Out-of-pocket costs impede PrEP use among young MSM in the private healthcare system. Presented at Conference on Retroviruses and Opportunistic Infections 2018.
10.
Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–7.CrossRef
11.
Touger R, Wood BR. A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP). Curr HIV/AIDS Rep. 2019;16(1):113–9.CrossRef
12.
Rendina HJ, Whitfield THF, Grov C, Starks TJ, Parsons JT. Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): findings from a large cohort of gay and bisexual men in the U.S. Social Sci Med. 2017;172:115–23.CrossRef
13.
Ellison J, Van Den Berg JJ, Montgomery MC, Tao J, Pashankar R, Mimiaga MJ, et al. Next-generation HIV pre-exposure prophylaxis preferences among men who have sex with men taking daily oral pre-exposure prophylaxis. AIDS Patient Care STDs. 2019;33(11):482–91.CrossRef
14.
Holt M, Murphy DA. Individual versus community-level risk compensation following preexposure prophylaxis of HIV. Am J Public Health. 2017;107(10):1568–71.CrossRef
15.
Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS ONE. 2013;8(9):e74314.CrossRef
16.
Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRef
17.
Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.CrossRef
18.
Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, et al. Daily and nondaily oral preexposure prophylaxis in men and transgender women who have sex with men: the human immunodeficiency virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2018;66(11):1712–21.CrossRef
19.
Molina J-M, Capitant C, Spire B, Pialoux, G., Chidiac C, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Paper presented at the Conference on retroviruses and opportunistic infections 2015.
20.
Siguier M, Mera R, Pialoux G, Ohayon M, Cotte L, Valin N, et al. First year of pre-exposure prophylaxis implementation in France with daily or on-demand tenofovir disoproxil fumarate/emtricitabine. J Antimicrob Chemother. 2019;74(9):2752–8.CrossRef
21.
Reyniers T, Nöstlinger C, Laga M, De Baetselier I, Crucitti T, Wouters K, et al. Choosing between daily and event-driven pre-exposure prophylaxis: results of a Belgian PrEP demonstration project. J Acquir Immune Defic Syndr. 2018;79(2):186–94.CrossRef
22.
Zimmermann HM, Eekman SW, Achterbergh RC, Schim Van Der Loeff MF, Prins M, Vries HJ, et al. Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis—a qualitative analysis. J Int AIDS Soc. 2019;22(10):e25389.CrossRef
23.
Vaccher SJ, Gianacas C, Templeton DJ, Poynten IM, Haire BG, Ooi C, et al. Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE demonstration project. Front Public Health. 2017;5:341.CrossRef
24.
Sewell WC, Powell VE, Mayer KH, Ochoa A, Krakower DS, Marcus JL. Nondaily use of HIV preexposure prophylaxis in a large online survey of primarily men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2020;84(2):182–8.CrossRef
25.
Shrestha R, Karki P, Altice FL, Dubov O, Fraenkel L, Huedo-Medina T, et al. Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. 2018;22(4):1228–38.CrossRef
26.
Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31(5):545–53.CrossRef
27.
Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.CrossRef
28.
Cohen SE, Kelley CF. Is the United States ready for event-driven human immunodeficiency virus preexposure prophylaxis? Clin Infect Dis. 2020;71(2):256–8.CrossRef
29.
Molina J-M, Ghosn J, Algarte-Genin M, Rojas-Castro D, Beniguel L, Pialoux G, et al. Incidence of HIV-infection with daily or on-demand PrEP with TDF/FTC in Paris area—update from the ANRS Prevenir Study. In: 10th IAS Conference on HIV Science: International AIDS Society. Hoboken: Wiley; 2019.
30.
World Health Organization. Technical brief: what’s the 2+ 1+ 1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO’s recommendation on oral PrEP. Geneva: World Health Organization; 2019.
31.
Department of Health and Mental Hygiene. “On-Demand” dosing for PrEP: guidance for medical providers. New York City: Department of Health and Mental Hygiene; 2019.
32.
Department of Health—Population Health Division; Important HIV prevention and treatment updates for San Francisco providers. San Francisco: Department of Health—Population Health Division; 2019.
33.
Department of Health. PrEP 2-1-1: “On-Demand” pre-exposure prophylaxis (PrEP) for sexual intercourse. California: Department of Health; 2019.
34.
Dimitrov D, Moore JR, Wood D, Mitchell KM, Li M, Hughes JP, et al. Predicted effectiveness of daily and nondaily preexposure prophylaxis for men who have sex with men based on sex and pill-taking patterns from the human immuno virus prevention trials network 067/ADAPT study. Clin Infect Dis. 2020;71(2):249–55.CrossRef
35.
Marks SJ, Merchant RC, Clark MA, Liu T, Rosenberger JG, Bauermeister J, et al. Potential healthcare insurance and provider barriers to pre-exposure prophylaxis utilization among young men who have sex with men. AIDS Patient Care STDs. 2017;31(11):470–8.CrossRef
36.
Spiegelman D, Easy SAS. Calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199–200.CrossRef
37.
SAS Institute Incorporated. SAS (Version 9.4). Cary: SAS Institute Incorporated; 2013.
38.
Doblecki-Lewis S, Butts S, Botero V, Klose K, Cardenas G, Feaster D. A randomized study of passive versus active PrEP patient navigation for a heterogeneous population at risk for HIV in South Florida. J Int Assoc Provid AIDS Care (JIAPAC). 2019;18:232595821984884.CrossRef
Metadata
Title
Predictors of Event-Driven Regimen Choice in Current PrEP Users and Sexual Behavior Characteristics of MSM Receiving Sexual Health Services in New York City
Authors
Pedro B. Carneiro
Christopher Rincon
Sarit Golub
Publication date
01-08-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03203-1

Other articles of this Issue 8/2021

AIDS and Behavior 8/2021 Go to the issue

Original Paper

Using Incentives and Nudging to Improve Non-Targeted HIV Testing in Ecuador: A Randomized Trial

Original Paper

HIV Stigma, Homophobia, Sexual and Gender Minority Community Connectedness and HIV Testing Among Gay, Bisexual, and Other Men and Transgender People Who Have Sex with Men in Kazakhstan

Original Paper

Use of Antiretroviral Therapy for a US Medicaid Enrolled Pediatric Cohort with HIV

Original Paper

Single Room Occupancy Residence: Processes Linking Housing to Not Engaging in HIV Outpatient Care

Original Paper

Network Characteristics Associated with HIV Testing Conversations Among Transgender Women in Los Angeles County, California

Original Paper

Stronger Together: Results from a Randomized Controlled Efficacy Trial of a Dyadic Intervention to Improve Engagement in HIV Care Among Serodiscordant Male Couples in Three US Cities

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits